Research Article
Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
Table 3
Sensitivity and specificity of three biomarkers with efficacy in predicting prostate cancer in patients with PSA 4–10 ng/mL.
| — | Criterion | Sensitivity | 95% CI | Specificity | 95% CI | +LR | −LR | +PV | −PV |
| PCA3 | 23.5 | 97.0 | 84.2–99.9 | 41.6 | 31.2–52.5 | 1.7 | 0.1 | 38.1 | 97.4 | 30.4 | 90.9 | 75.7–98.1 | 43.8 | 33.3–54.7 | 1.6 | 0.2 | 37.5 | 92.9 | 35.4 | 81.8 | 64.5–93.0 | 46.1 | 35.4–57.0 | 1.5 | 0.4 | 36.0 | 87.2 | 214.3 | 27.3 | 13.3–45.5 | 89.9 | 81.7–95.3 | 2.7 | 0.8 | 50.0 | 76.9 |
| PSGR | 24.2 | 90.9 | 75.7–98.1 | 20.2 | 12.4–30.1 | 1.1 | 0.5 | 29.7 | 85.7 | 93.0 | 81.8 | 64.5–93.0 | 49.4 | 38.7–60.2 | 1.6 | 0.4 | 37.5 | 88.0 | 623.3 | 12.1 | 3.4–28.2 | 96.6 | 90.5–99.3 | 3.6 | 0.9 | 57.1 | 74.8 |
| MALAT-1 | 32.8 | 90.9 | 75.7–98.1 | 25.8 | 17.1–36.2 | 1.2 | 0.4 | 31.3 | 88.5 | 109.6 | 72.7 | 54.5–86.7 | 60.7 | 49.7–70.9 | 1.9 | 0.5 | 40.7 | 85.7 | 156.5 | 54.6 | 36.4–71.9 | 78.7 | 68.7–86.6 | 2.6 | 0.6 | 48.6 | 82.4 |
| PSA | 9.6 | 90.9 | 75.7–98.1 | 11.2 | 5.5–19.7 | 1.02 | 0.81 | 27.5 | 76.9 | 7.95 | 72.7 | 54.5–86.7 | 39.3 | 29.1–50.3 | 1.20 | 0.69 | 30.8 | 79.5 | 5.1 | 18.18 | 7.0–35.5 | 91.0 | 83.1–96.0 | 2.02 | 0.90 | 42.9 | 75.0 |
| % fPSA | 21.9 | 90.9 | 75.7–98.1 | 28.1 | 19.1–38.6 | 1.26 | 0.32 | 31.9 | 89.3 | 23.2 | 100.0 | 89.4-100.0 | 24.7 | 16.2–35.0 | 1.33 | 0.00 | 33.0 | 100.0 | 9.1 | 21.2 | 9.0–38.9 | 89.9 | 81.7–95.3 | 2.10 | 0.88 | 43.7 | 75.5 |
|
|
Indicating the cutoff value of the Youden index. PA: predictive accuracy; +LR: positive likelihood ratio; −LR: negative likelihood ratio; +PV: positive predicted value; −PV: negative predicted value.
|